Hold off on inoculating people ages 60 and older against chikungunya infection with the Ixchiq vaccine, the FDA and CDC ...

Antibiotic use in the first 3 month of life was associated with a 23% increase in risk of early puberty in girls.

In a statement today, the company said it supports recent precautionary measures and that thorough investigations are needed ...

New research reveals the potential of drugs that have been on the market for decades to treat diseases other than those for ...

Reports of severe adverse events in some people who received the chikungunya vaccine have spurred regulators in Europe and ...

THE001, a thermosensitive doxorubicin liposome for soft tissue sarcomas, received FDA orphan drug designation, offering ...

The findings show access to Tofersen, the first effective new motor neurone disease (MND) treatment for decades, has become a ...

On the heels of similar moves in France and the European Union, U.S. health authorities are calling for a pause in the use of ...

Biodexa Receives Orphan Drug Designation in Europe for eRapa in FAP New designation follows the U.S. Food and Drug Administration (FDA) Orphan Drug Designation for eRapa in FAP granted ...

Adds nine additional countries to the Company's ongoing pivotal Phase 3 trial; Authorization granted in all EU countries requested Enrollment and dosing underway in Phase 3 clinical trial (the "MIRACL ...

BEIJING, CHINA / ACCESS Newswire / May 12, 2025 / CASI Pharmaceuticals, Inc. (Nasdaq:CASI), ("CASI" or the "Company"), a Cayman incorporated biopharmaceutical company focused on developing and ...

Adds nine additional countries to the Company’s ongoing pivotal Phase 3 trial; Authorization granted in all EU countries ...